Evidence map›Paper›PMID 40089888›Full record

ReviewProblemy endokrinologii2024

[Female reproductive function after radioiodine therapy for differentiated thyroid carcinoma].

M O Korchagina, E N Andreeva, M S Sheremeta, G A Melnichenko

Abstract readReviewEnglish Abstract
In one paragraph

Review in Problemy endokrinologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M O KorchaginaEndocrinology Research Centre.
E N AndreevaEndocrinology Research Centre; Russian university of medicine.
M S SheremetaEndocrinology Research Centre.
G A MelnichenkoEndocrinology Research Centre.

Funding

Non-US Government Research Support type
6 · The paper itself

Abstract

Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer, accounting for 90-95% of thyroid malignancy and predominant in the female population of all age groups. Surgery is the standard primary treatment for patients with DTC, followed by radioactive iodine therapy (RAIT) when indicated. After the main treatment, patients receive thyroid hormone therapy in a variety of regimens, either as a replacement therapy or as a therapy intended to suppress secretion of thyroid-stimulating hormone (TSH).The impact of RAIT on the health of individuals with DTC has been studied for years. The accumulation of 131I in organs and tissues, as well as some organs' direct involvement in the metabolism of 131I-containing substances and its excretion, can lead to secondary complications. Reproductive health in the context of RAIT has also been a popular research topic because DTC is frequently found in young individuals.We may identify a direction for future study in this field and the requirement for adjustments in patient management thanks to the data summarized in this review on the effect of RAIT for DTC on female reproductive health.

Indexed as

Iodine RadioisotopesReproductionThyroid NeoplasmsFemaleHumansIodine Radioisotopes

Identifiers

PMID40089888
PMCPMC11931471

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.